Joined September 2009
7 Photos and videos
Sandro Cosconati retweeted
20 Mar 2025
We're hiring!🚨Our lab @SydneyChemistry is looking for two new #chempostdoc for our drug discovery program: 1) Synthetic/Med Chem (small molecule hit-to-lead)🧪 usyd.wd3.myworkdayjobs.com/e… 2) Chemical Biology (peptide inhibitors)🦠 usyd.wd3.myworkdayjobs.com/e… Pls spread the word!šŸ™
3
69
159
28,673
Sandro Cosconati retweeted
21 Feb 2025
ESMEC 2025 URBINO - European School of Medicinal Chemistry: June 29 – July 3, 2025 Tentative Programme Available and REGISTRATION is nor OPEN! For all the info: esmec.eu We are waiting for you in Urbino! @DCFSCI @EuroMedChem @YoungSciNet @SciGiovani
7
11
458
Sandro Cosconati retweeted
On the issue 1 cover is work by Sabrina Taliani, Floriana Morgillo, @scoscona & co on the discovery ofĀ c-MET/SMO modulators in EGFRi-resistant non-small cell lung cancer, take a look⬇ pubs.rsc.org/en/content/arti… šŸ“@unicampania @Unipisa Read the full issuešŸ‘‰pubs.rsc.org/en/journals/jou…
1
2
389
Our manuscript is now featured on the front cover of @JCIM_JCTC! Huge thanks to the talented @ben_nitro93 and @MicheleRoggia99 for creating this amazing cover art! #MyACSCover @ACS4Authors
3
13
977
Sandro Cosconati retweeted
Discovering Dually Active Anti-cancer Compounds with a Hybrid AI-structure-based Approach @JCIM_JCTC 1/ In this study, a novel hybrid AI-structure-based approach was developed to identify compounds that can target both G-quadruplex (G4) structures and the poly(ADP-ribose) polymerase (PARP1) enzyme, opening the door to innovative cancer therapies with dual action. 2/ The innovative two-step virtual screening protocol integrates machine learning and structure-based methods. PyRMD, an AI-powered tool, identifies potential PARP1 inhibitors from vast chemical libraries, then evaluates them for their G4 stabilization potential. 3/ By combining AI and structure-based screening, the study identifies four compounds with dual PARP1 inhibition and G4 stabilization activity, offering a multipronged strategy to disrupt cancer cell proliferation. 4/ The identified compounds show significant antiproliferative activity, particularly against cancer cell lines with BRCA1 mutations, suggesting the potential for targeting tumors with DNA repair deficiencies. 5/ One compound, in particular, demonstrated activity against telomerase-positive HeLa cells, hinting at its broader applicability across different cancer types, making it a versatile therapeutic candidate. 6/ This study showcases the potential of hybrid AI-driven approaches in drug discovery, emphasizing the power of combining machine learning with classical structure-based methods to develop multitarget anticancer compounds. @scoscona šŸ“œPaper: doi.org/10.1021/acs.jcim.4c0…
1
6
21
2,179
Sandro Cosconati retweeted
3 Sep 2024
šŸ“£ Session 9 – Prof. Sandro COSCONATI from @unicampania is now on the stage for talk titled ā€œFrom Reversible to Irreversible Peptide Inhibitors of the TRF2TRFH Recruiting Functions: a Strategy to Induce Replication Stress in Cancer Cellsā€. Stay tuned! šŸ”¬šŸ’” #EFMCISMC24 #MedChem
2
9
524
Sandro Cosconati retweeted
Next talk in the peptide session at #EFMCISMC24 is given by Sandro Cosconati (@scoscona), describing his strategy to induce replication stress in cancer cells, from reversible to irreversible peptide inhibitors of the TRF2TRFH recruiting functions. @EuroMedChem @DCFSCI
1
13
521
Take a peek at my cover art accepted for the 21 Dec issue of @CellChemBiol! Gratitude to @AIRC_it for supporting my research and shout-out to fellow authors @hildaApickett, @sadimaro80, and Alex Sobinoff. #drugdiscovery #CancerResearch
3
12
1,998
Sandro Cosconati retweeted
Online now! Irreversible inhibition of TRF2TRFH recruiting functions by a covalent cyclic peptide induces telomeric replication stress in cancer cells by Alexander Sobinoff, Salvatore Di Maro, @hildaApickett, @scoscona, et al dlvr.it/SzrGYZ #chembiol

2
4
1,011
Our latest paper in @CellChemBiol unveils APOD53, an antiproliferative cyclic peptide co-discovered with @PicketHilda and @TheCesareLab to bind TRF2. Kudos to first authors @sadimaro80 and Alex Sobinoff! Special thanks to @AIRC_it for their support. authors.elsevier.com/c/1iDJY…

1
2
12
1,939
APOD53's impact goes beyond inhibiting TRF2; it blocks the interaction of RTEL1 and SLX4 with TRF2, inducing replication stress, DNA damage, and telomere fragility. This sets the stage for a robust telomeric DNA damage response.
1
1
1
157
Co-treatment with the G4 stabilizing agent RHPS4 amplifies APOD53's effects on telomeric replication stress, offering a potential combination strategy for cancer treatment. The interplay between TRFH targeting peptides and replication stress inducers is explored.
1
2
129
Our work identified APOD41 as a cell-permeable TRF2 binder. To enhance its efficiency, we modified APOD41 derivatives with reactive species, turning them into covalent binders. The goal: disrupt TRF2 functions more effectively. #covalentmodifiers #drugdiscovery #drugdevelopment
1
1
69
APOD53, a cysteine-binding acrylamide Michael acceptor modifier, forms covalent adducts with the TRF2TRFH peptide. Compared to its predecessor APOD41, APOD53 emerges as a more potent inhibitor of cellular viability, especially in cancer cells.
62